The project aims to develop new and improved medicines for schizophrenia, bipolar disorder and major depression, estimated by the EU as some of the most costly diseases for both society and patients, which is of key importance for psychiatry as current medicines are far from optimal and have a number of undesirable side effects. The research is based on extremely urgent clinical problems and aims to identify, using advanced basic science methodology and selective pharmacological tools, new targets for drugs that can be used in psychosis and bipolar disorder as well as in major depression. This includes some new antipsychotic drugs, such as asenapine, but also so-called allosteric AMPA receptor potentiators and glycine uptake inhibitors, as well as direct and indirect nicotinic alpha7 receptor agonists, which have recently been shown to have therapeutic effects in schizophrenic patients. Our research can stimulate drug development in the field that is currently losing momentum, not least in Sweden. The results have been met with great interest both among psychiatrists and the international pharmaceutical industry.